drugset / Trial / NCT03978637
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of itacitinib in participants with post-lung transplant bronchiolitis obliterans syndrome (BOS).
Timeline
- Start
- 2020-02-04
- Primary completion
- 2023-10-13
- Completion
- 2023-10-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itacitinib | Small molecule | 300 mg | Oral |
| Subject | Itacitinib | Small molecule | 400 mg | Oral |
| Subject | Itacitinib | Small molecule | 600 mg | Oral |